BRD2 and ovarian carcinoma: Concerning clinical stages, BRD2 and BRD3 in advanced stage (III+IV), and BRDT in all clinical stages (I+II, III+IV) were associated with the better OS in ovarian cancer patients, although high BRD4 mRNA level showed worse OS in early-stage (I+II) patients with ovarian cancer (Table 2).